⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 13, 2018Expert Opinion on Therapeutic TargetsOpen Access

The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Share

Abstract

KEYWORDS: Acute myeloid leukemiaBrequinarDHODHdifferentiationmetabolismnucleotidespyrimidinestherapeutic window

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

David B. Sykes (2018) studied this question.

synapsesocial.com/papers/6a0193ac6f2c4fd2e25c999e https://doi.org/10.1080/14728222.2018.1536748

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cellsOriginal Research · 2009 · 112 citations
2Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase InhibitorsOriginal Research · 2018 · 73 citations
3Adaptive Reprogramming of <i>De Novo</i> Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast CancerOriginal Research · 2017 · 198 citations
4PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase InhibitionOriginal Research · 2017 · 136 citations
5PTK7-targeted cancer therapies: molecular understanding and clinical developmentsExpert Opinion on Therapeutic Targets · Sun,

More from Expert Opinion on Therapeutic Targets

Targeting the microbiota-gut-brain axis in Alzheimer’s and Parkinson´s disease: recent therapeutic approachesFri,
Molecular basis for developing tumor-targeted siRnas for future immunotherapyTue,
Overcoming adaptive resistance to cancer immunotherapy: molecular targeting strategies for the tumor microenvironmentFri,
Targeting protein misfolding and aggregation in neurodegenerative diseases: challenges for the identification and validation of targets for small moleculesFri,
VAV1 targeting for cancer therapeutics: mechanistic understanding and preclinical promiseFri,